BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) announced that its compensation committee granted inducement equity to four newly hired employees effective Dec 1, 2025. The grants consist of stock options to purchase an aggregate of 57,100 shares and restricted stock units covering 46,400 shares, totaling 103,500 shares.

The options have an exercise price of $7.13 per share, equal to the closing price on the grant date, a 10-year term, and the options and RSUs vest in four equal annual installments beginning on the one-year anniversary, subject to continued service. Grants were made under BioCryst’s Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

+0.06%

1 alert

+0.06% News Effect

On the day this news was published, BCRX gained 0.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stock options granted: 57,100 shares RSUs granted: 46,400 shares Total inducement equity: 103,500 shares +3 more

6 metrics

Stock options granted 57,100 shares Inducement grants to four newly hired employees as of Dec 1, 2025

RSUs granted 46,400 shares Inducement RSUs to four newly hired employees as of Dec 1, 2025

Total inducement equity 103,500 shares Aggregate of options and RSUs granted to new hires

Option exercise price $7.13 per share Equal to BCRX closing price on Dec 1, 2025 grant date

Option term 10 years Term of inducement stock options granted Dec 1, 2025

Vesting schedule 4 equal annual installments Options and RSUs vest over four years from one-year anniversary

Market Reality Check

Price: $6.66 Vol: Volume 2,615,941 is below...

low vol

$6.66 Last Close

Volume Volume 2,615,941 is below the 20-day average of 3,890,132 (about 0.67x average activity). low

Technical Shares trade below the 200-day MA of 8.28, with the stock at 7.58.

Peers on Argus

Peer moves were mixed and modest, with AVDL down 0.37% while HROW, PAHC, BGM, an...

Peer moves were mixed and modest, with AVDL down 0.37% while HROW, PAHC, BGM, and AMPH rose between 0.35% and 1.98%, suggesting today’s slight 0.26% gain in BCRX was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Inducement grants	Neutral	+0.1%	Disclosure of options and RSUs for four new hires under inducement plan.
Dec 03	M&A regulatory step	Positive	+9.6%	Early termination of HSR waiting period for Astria acquisition regulatory clearance.
Nov 12	Astria earnings & update	Positive	-0.7%	Astria Q3 results and strong HAE trial data tied to planned BioCryst acquisition.
Nov 06	Clinical data update	Positive	-1.9%	Pediatric ORLADEYO data and FDA review timeline for oral granule formulation.
Nov 05	Inducement grants	Neutral	+6.1%	Inducement RSUs for three new employees vesting over four years.

Pattern Detected

Regulatory and clinical milestones have driven clearer reactions than routine inducement grants, which have produced small or mixed price moves.

Recent Company History

Over the last months, BioCryst reported several corporate and clinical milestones. Inducement equity grants on Nov 5 and Dec 1, 2025 added modest share-based compensation, with limited price impact. More material events included the Astria cash-and-stock acquisition and early HSR termination on Dec 3, 2025, which saw a 9.64% gain. Positive pediatric HAE data for ORLADEYO on Nov 6, 2025 and Astria’s trial and financial update on Nov 12, 2025 had mixed or negative short-term reactions.

Market Pulse Summary

This announcement detailed standard inducement equity awards for four new employees, totaling 57,100...

Analysis

This announcement detailed standard inducement equity awards for four new employees, totaling 57,100 option shares and 46,400 RSUs at an exercise price of $7.13. The options have a 10-year term and both options and RSUs vest in four equal annual installments, reinforcing a long-term retention structure. Within the recent context of M&A activity and clinical updates, this filing mainly adds modest share-based compensation rather than altering the fundamental outlook.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, stock options, exercise price

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"and restricted stock units (RSUs) covering an aggregate of 46,400 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The options have an exercise price of $7.13 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock. The options and RSUs were granted as of December 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $7.13 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What equity did BioCryst (BCRX) grant on Dec 1, 2025?

BioCryst granted stock options for an aggregate of 57,100 shares and RSUs covering 46,400 shares, effective Dec 1, 2025.

What is the exercise price and term for the BioCryst (BCRX) options?

Each option has an exercise price of $7.13 (equal to the grant-date close) and a 10-year term.

How do the options and RSUs vest for the BCRX inducement grants?

The options and RSUs vest in four equal annual installments starting on the one-year anniversary of the grant, subject to continued service.

Under what plan and Nasdaq rule were the BioCryst inducement grants made?

The awards were granted under BioCryst’s Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement grants from BioCryst on Dec 1, 2025?

The compensation committee granted inducement equity to four newly hired employees.